The Use of Inhaled Nitric Oxide in the Management of Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome (ARDS) Patients' Lung Function (PLF), Morbidity (M), and Death were the primary outcomes the researchers were interested in examining. The standard therapy, or the inhaled nitric oxide inhNO treatment, was administered to 30 ARDS patients divided into two groups. It has been shown that 0.5 to 40 ppm of inhNO is the ideal daily dosage. All treatment methods were standard. In 25% of ARDS Patients, sepsis was the underlying cause. In the first 24 hours after inhNO, patients had a considerable increase in their hypoxia score, from 114.2 to 170.4 mm Hg. Similar decreases in venous admixture also occurred in the inhNO group to the control group. InhNO did not continue to have any positive effects beyond the first day of therapy. Forty percent of the inhNO group remained alive and weaned off mechanical ventilation thirty days following randomization, whereas only 33.3% of the control group did so. With Multiple Organ Failure Syndrome (MOFS) as the primary cause of death, the 30-day mortality rate for both groups was comparable. According to the research, inhNO might improve gas exchange but did not lower mortality in this group.